FK866 attenuates receptor activator of nuclear factor kappa-B ligand-induced osteoclastogenesis
10.11620/IJOB.2025.50.1.17
- Author:
Chang Youp OK
;
Hye-Ock JANG
;
Moon-Kyoung BAE
;
Soo-Kyung BAE
- Publication Type:Original Article
- From:International Journal of Oral Biology
2025;50(1):17-25
- CountryRepublic of Korea
- Language:English
-
Abstract:
Visfatin, an adipokine secreted by cells, is crucial for intracellular nicotinamide adenine dinucleotide + biosynthesis.Extracellularly, visfatin plays diverse roles in inflammatory conditions, including obesity, which is closely linked to osteoclastogenesis. We previously showed that visfatin enhances receptor activator of nuclear factor kappa-B ligand (RANKL)-induced osteoclastogenesis in bone marrow-derived macrophages. However, its enzymatic activity during this process is poorly understood. Here, we investigated visfatin’s effects on RANKL-induced osteoclast differentiation. Our results demonstrate that visfatin promotes this differentiation, an effect inhibited by FK866, an inhibitor of visfatin’s enzymatic activity. Furthermore, FK866 also inhibited RANKL-induced osteoclast differentiation.These findings suggest that inhibiting visfatin’s enzymatic activity modulates osteoclast differentiation. Thus, visfatin plays an important role in osteoclastogenesis, both intracellularly and extracellularly, and FK866 has therapeutic potential for diseases characterized by imbalanced osteoclast formation, such as osteoporosis and periodontitis.
